Poster Session A
Systemic lupus erythematosus (SLE)
Kohei Tsujimoto, MD, PhD
Osaka University
Suita, Osaka, Japan
No financial relationships with ineligible companies to disclose
Patients who received biologic agents (belimumab, anifrolumab, or rituximab; n=45, 5, and 3, respectively) were identified. The group that received early introduction of biologic agents required a lower maintenance PSL dose compared to the group that received biologic agents in the maintenance phase (mean of early group: 3.658 mg [95% confidence interval:2.862-4.453], mean of late group: 5.771 mg [3.993-7.548], p=0.0456) (Figure 1). Additionally, the early introduction group experienced a significant reduction in relapse rates [Log-rank test, p=0.0310] (Figure 2).
Conclusion:
Early introduction of biologic agents in SLE not only suppresses disease relapse but also enables a reduction in the maintenance PSL dose. The early introduction of biologic agents may positively impact long-term outcomes over a period of 3 years.
T. HIrayama: None; K. Tsujimoto: Chugai, 12, As a specially appointed assistant professor of an endowed chair, I indirectly received salary payments; K. Kaneko: None; S. Isojima: None; K. Ichinose: Asahi Kasei Pharma, 6, AstraZeneca, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6; Y. Iwata: None; K. Oku: None; K. Sada: GlaxoSmithKlein(GSK), 6; Y. Tanaka: AbbVie, 6, Asahi-kasei, 6, Astellas, 6, AstraZeneca, 6, Boehringer Ingelheim, 5, 6, Chugai, 5, 6, Daiichi Sankyo, 6, Eisai, 6, Gilead, 6, GSK, 6, Lilly, 6, Pfizer, 6, Taisho, 5, 6, UCB, 6; A. Nakajima: None; K. Fujio: AbbVie/Abbott, 5, 6, Alexion, 6, Asahi Kasei Pharma, 1, 2, 5, 6, AstraZeneca, 5, 6, Bristol-Myers Squibb(BMS), 5, 6, Chugai Pharmaceutical, 5, 6, Daiichi-Sankyo, 6, Eisai, 5, 6, Eli Lilly, 6, Gilead, 6, GlaxoSmithKlein(GSK), 6, Mitsubishi Tanabe Pharma, 6, Novartis, 6, Pfizer, 6, Taisho Pharmaceutical, 5, 6, Tsumura, 5; M. Matsushita: None; T. Miyamae: None; A. Murashima: Chugai, 6; A. Kumanogoh: Asahi-Kasei, 6, Astellas, 6, Boehringer-Ingelheim, 6, Bristol-Myers Squibb(BMS), 6, Chugai, 5, 6, Eisai, 2, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Pfizer, 6.